1. INTRODUCTION {#sec1}
===============

In the present scenario, both hypertension and diabetes mellitus are the most common killer diseases among top ten non-communicable diseases having high mortality rates in Asia, America and Europe \[[@r1], [@r2]\]. Hypertension alone is a risk factor for the induction of other complications such as angina pectoris, brain stroke, heart failure and end stage renal disease \[[@r3]\]. According to World Health Organization (WHO), the prevalence of hypertension is escalating year by year throughout the world and around 17 million peoples (31% of all deaths in the world) die per year due to cardiovascular diseases, among which, hypertension alone contributing for approximately 9.4 million deaths per year \[[@r4]\]. As per the Joint National Committee VIII guidelines, recommended the drugs for the first line drug therapy as follows angiotensin converting enzyme inhibitors (ACE inhibitors), diuretics, beta blockers (BB), calcium channel blockers (CCB) and angiotensin receptor blockers (ARB) \[[@r5]\]. Many debates conducted on the duration of onset of diabetes mellitus after the chronic treatment of BBs, diuretics and CCBs \[[@r6]-[@r10]\]. Some of the clinical studies reported that an antihypertensive treatment either as a mono-therapy or as a combination therapy for more than 3 to 6 years showed to induce the onset of diabetes mellitus instead of anti hypertensive effect \[[@r11], [@r12]\]. All antihypertensive drugs have almost similar beneficial outcome for the treatment of high blood pressure but differ in their potential of causing adverse events such as disturbance in blood glucose homeostasis leading to induction of diabetes \[[@r13]\]. This disturbance in glucose homeostasis and elevation in blood glucose level during antihypertensive therapy is also associated with future cardiovascular events \[[@r14]\].

The interaction of rennin-angiotensin system and gene polymorphism may be responsible for regulation of onset of diabetes in hypertensive patients after treated with diuretics and beta blockers. The inter-individual difference in drug response of anti hypertensive therapy and new onset of diabetes in some patients can be explained on the basis of genetic polymorphism related to metabolic functions. Hence, Genetic polymorphism of genes (which influence the pathophysiology of hypertension and diabetes) may be responsible for new onset of diabetes under the influence of certain antihypertensive drugs due to alteration in physiological processes.

Gly460Trp polymorphism of alpha adducin-1 gene (ADD1) may be one of those genes which may affect the physiological processes related to hypertension and diabetes under the influence of antihypertensive therapy, especially with diuretics and BBs. ADD1 is the part of adducin family which is a heterodimeric cytoskeleton protein \[[@r15]\]. It is a salt-sensitive gene associated with increased renal sodium re-absorption *via* activation of Na^+^-K^+^ATPase pump. The polymorphic alleles of ADD1 gene may show variations in the amount of sodium reabsorbed and potassium excreted counter to sodium ion and results in physiological change \[[@r16]\]. Studies have shown that 460W allele is associated with more sodium re-absorption than 460G allele; therefore, 460W allele is at more risk of developing salt-sensitive hypertension \[[@r17]\]. Therefore, 460W allele must be associated with excretion of more potassium *via* Na^+^-K^+^ATPase pump as a counter ion to sodium. Potassium is considered to have a major role in glucose homeostasis *via* affecting the release of insulin as well as insulin-mediated glucose uptake into skeletal muscle. It has been well studied that hypokalemia may result in glucose disturbance \[[@r18], [@r19]\].

It is also found that, 460W allele is more prominent blood pressure reduction as compared to 460G allele after diuretic therapy \[[@r20]\]. More and quick reduction in blood pressure is associated with higher glomerular filtration rate (GFR) which is further associated with diabetes. So 460W allele may be associated with diabetes in hypertensive patients after diuretics treatment \[[@r21]\]. The T allele (460W) of salt sensitive ADD1 gene was found to be associated with higher risk of diabetes with diuretic therapy as compared to other alleles, although the significance level was very low, but it might be due to less population size \[[@r22]\].

The ADD1 gene polymorphism may be susceptible to the risk of diabetes by one or more of the above mentioned mechanisms. However, some studies deny the role of ADD1 gene polymorphism in risk of new onset of diabetes.

Therefore, in the present study, we attempted to access the role of ADD1 gene polymorphism during antihypertensive treatment causes the onset of diabetes.

2. MATERIAL AND METHODS {#sec2}
=======================

2.1. Methods {#sec2.1}
------------

### 2.1.1. Ethics {#sec2.1.1}

The study was approved (IEC/670) by the Institutional Ethics Committee of M. M. University and written consent was obtained from all the participants.

2.2. Design and Sample Size {#sec2.2}
---------------------------

The study was carried out on the basis of cross-sectional survey by M. M. Institute of Medical Science & Research, Mullana (Haryana), there are around 38,500 inhabitants residing in 17 villages of this rural area. The survey recorded a total of 2672 individuals afflicted with essential hypertension. These patients will be referred to as hypertensive (HT) with a disease prevalence of 6.94%. Out of 2672 patients, we have selected 510 patients who visited regularly in hospital OPD. A sample size of 164 patients will be sufficient to represent the hypertensive population residing in the rural area under investigation with a power of 80% and a *P-*value of 0.05. Patients who agree to participate were explained the nature and the objectives of the study, and informed consent was obtained individually. The information about patient's identity was not included with other data and only the consulting physician had the access to this information.

2.3. Study Population {#sec2.3}
---------------------

In the present investigation, the subjects under study (n=510) were divided into 2 groups with age and sex matched, 1) Essential Hypertensive (EH) 2) Essential hypertensive with the onset of diabetes (EHNOD). 1) The first group comprised of 270 hypertensive patients had 95 male and 175 females 2) Second group consisted of 240, hypertensive with diabetes patients, out of which 80 male and 160 females. In order to made comparison with normal individuals, we have selected normal individuals (n=270) with age and sex matched from the same place and denoted as the third group consists of 150 male and 120 females. Various parameters like age, sex, body mass index (BMI), blood pressure, education, and family history were recorded in a given questionnaire.

2.4. Inclusion Criteria {#sec2.4}
-----------------------

Patients residing in rural area of Haryana for more than two generations were recruited. They were the age of 18 years to 75 years with an average blood pressure limits \>140mmHg systolic blood pressure (SBP) and \> 90 mmHg diastolic blood pressure (DBP) on three separate occasions.

1.  For essential hypertensive group \[EH\]: Only those patients who had essential hypertension and were treated with selective antihypertensive medication (Diuretics, BBs, CCBs) as mono or in combination for about 3 years or more.

2.  For essential hypertensive with new onset of diabetes mellitus \[EHNOD\]: Only those patients who had EH (as per above criteria) with onset of diabetes mellitus (diagnosed according to WHO criteria as either a fasting plasma glucose \> 7.0 mmol/L and/or random (non-fasting) blood glucose \> 11.1 mmol/L) and were treated with selective antihypertensive medication (Diuretics, BBs, CCBs) as mono or in combination for about 3 years or more.

3.  Normotensives \[NT\]: Those who were residing in the rural area of Haryana without any history of hypertension or diabetes between the ages of 18 years to 75 years.

2.5. Exclusion Criteria {#sec2.5}
-----------------------

All individuals with the age less than 18 years or above 75 years are spared. Essential hypertensive patients who were treated with other than diuretics, BBs and CCBs alone or in combination were excluded. Pregnant and lactating mothers were removed from the study.

2.6. Blood Pressure Measurements {#sec2.6}
--------------------------------

The blood pressure recordings were taken by the physicians in OPD. We verified blood pressure with a mercury sphygmomanometer at least twice a week before enrollment. Patients were made to sit quietly for at least 15 minutes in a chair. Intakes of caffeine, exercise, smoking and drugs (which may affect blood pressure) were avoided for at least 30 minutes prior to the measurement. Three readings were taken at 5 minutes interval, and the average was recorded. If there was gross variation in them, a fourth reading was obtained and used for the diagnosis of hypertension. Blood Pressure was measured in both arms and in the event of any difference, the higher reading was taken. An appropriately sized cuff (cuff bladder encircling at least 80 percent of the arm) was used to ensure accuracy in palpitatory obliteration of radial pulse pressure which was obtained before ausculating for BP measurement. By the auscultatory method, appearance and disappearance of Korotkoff sound were taken as an indicator of systolic and diastolic BP, respectively \[[@r23]\].

2.7. Collection of Blood Sample {#sec2.7}
-------------------------------

The blood samples were collected in tubes containing EDTA as an anticoagulant. The samples were transported on ice to the laboratory and were processed on the same day \[[@r24]\].

2.8. Glucose Monitoring {#sec2.8}
-----------------------

The blood glucose levels were monitored after the patient complaint and had a symptom of diabetes mellitus that were treated with chronic therapy of diuretics, beta blockers and calcium channel blockers alone or in combination in the treatment of essential hypertension.

2.9. Genotyping for *ADD1* {#sec2.9}
--------------------------

DNA samples were isolated from peripheral blood lymphocytes by the standard modified inorganic method as described by Miller *et al*. \[[@r25]\], and quantified following standard spectrophotometric analysis. The isolated DNA samples were stored at -20°C till further analysis. The substitution of nucleotides from G-to-T resulted in the genetic variant of amino acid residue at 460 and was located at nucleotide position 614 of exon 10 of the ADD1 (Gen bank accession number L29294). The Gly460Trp polymorphism of ADD1 (rs4961) was detected using an Amplification Refractory Mutation System polymerase chain reaction (PCR). The following primer sets were used:

**F614G**5'-GGGGCGACGAAGCTTCCGAGGTA*G*-3'; (Forward-G allele specific primer)

**F614T**5'-GCTGAACTCTGGCCCAGGCCGACGAAGCTTCCGAGGATT-3'; (Forward-T allele specific primer)

**R614** 5'-CCTCCGAAGCCCCAGCTACCCA-3', (Reverse primer)

The polymerase chain reaction was carried out in thermal cycler (Bio-Rad, Japan) in total volume of 25 µl in 0.2 ml PCR tubes containing 2 µl (40 ng) of template DNA, 5.5 µl master mix (containing Taq polymerase, loading dye, dNTPs, Mgcl~2~ and buffer 10X), 1 μl (F614G primer, F614T primer and common primer (R614)), and 16.5μl nuclease free water. Initial denaturation was carried out at 94 °C for 10 minutes followed by 35 amplification cycles at 94 ºC for 20 seconds, primer annealing at 60º C for 30 seconds, initial extension at 72 ºC for 30 seconds and final extension step at 72 °C for 3 minutes. The amplified DNA samples were separated using gel electrophoresis (4% agarose gel) and observed under UV documentation chamber to find type of genotype present *i.e*. GG, TG, or TT genotype \[[@r23], [@r26]\]. The size of PCR products were 220 bp and 234 bp for the 460Gly and 460Trp alleles, respectively (NuSieve, 3:1 agarose, FMC Bioproducts).

2.10. Statistical Analysis {#sec2.10}
--------------------------

Data analysis was done with the help of an SPSS version 14.5. Continuous variables are expressed as means ± SD. Intergroup comparisons are made using ANOVA with multiple comparison with post-hoc test. Allele frequencies were calculated from genotype frequencies and were compared using chi-squared (χ^2^) statistics. *P* value [\<]{.ul} 0.05 was considered statistically significant.

3. RESULTS {#sec3}
==========

3.1. Study Populations and Baseline Characteristics {#sec3.1}
---------------------------------------------------

A study population comprised of 510 (EH and EHNOD) patients and 270 normotensive individuals. Among patients, 270 were EH and 240 were EHNOD after treated with chronic anti hypertensive therapy. Out of 270 in hypertensive group, 175 were females and 95 were males same in the case of EHNOD, they were 160 females and 80 males. As per Table **[1](#t1){ref-type="table"}**, all baseline parameters showed significant changes (*p\<0.0001*) in comparison of different groups. Height could not show any significant change in multiple comparisons between normotensive versus essential hypertensive and essential hypertensive with new onset of diabetes. In blood pressure levels (SBP and DBP), there was statistically higher significance among all three groups. In fasting blood glucose levels (FBG), the average FBG levels were 207.29 ± 81.02 mg/dl in EHNOD than 107.20±7.85 mg/dl in EH whereas average normotensive showed 97.1±6.6 mg/dl. It was statistical higher significant. Among anthropometric parameters, BMI, waist circumference (WC) and waist-hip ratio (W/H) were showed higher statistical significant (*p\<0.0001*) when compared between all three groups in each parameter. The average duration of hypertension in both the groups \[EH and EHNOD\] were 4.70 ± 4.11 and 7.91 ± 4.52 years respectively and total duration of diabetes after treatment with anti hypertensive therapy was 5.72 ± 4.32 years respectively in EHNOD.

The gel picture (Fig. **[1](#f1){ref-type="fig"}**) represented the different genotypes of ADD1 gene. Table **[2](#t2){ref-type="table"}** represented genotype and the allelic distribution of EH versus normotensive group. GG homozygote was higher in percentage than TG and TT genotypes in both the groups \[EH and EHNOD\]. Non- statistical significance was found in patients and control according to Hardy-Weinberg equilibrium. Frequency of G allele was 0.813 than T allele (0.187) of EH group same in the case of EHNOD, it was 0.813 of G allele and 0.707 had T allele whereas in normotensive group, the T allele was 0.167 and G allele was 0.833.

Table **[3](#t3){ref-type="table"}** represented the distribution of genotypes with respect to various clinical and anthropometric parameters of EH patients. In anthropometric parameters, only height showed statistical significant difference (p =0.009) among different genotypes of total population and in male population only. In female specific, only waist circumference showed a slightly significant change (p=0.004) in comparison with different genotypes. Blood pressure levels and fasting blood glucose both showed statistical good significant. The duration of hypertension was also showed statistically significant (p=0.005) difference in male specific group and total population in comparison with different genotypes.

While, in case of essential hypertension with new onset of diabetes (Table **[4](#t4){ref-type="table"}**), the age of total population showed statistical lesser significant (p=0.02) when compared between different genotypes. According to gender wise, only BMI of male population showed slightly significant (p=0.033) between different genotypes as compared to other parameters. Duration of hypertension was also showed non-significant.

Table **[5](#t5){ref-type="table"}** represented the genotype distribution with respect to drug therapy in male and female population of hypertensive patients. In male patients, both the blood pressure \[SBP (p=0.0087), DBP (*p\<0.0001*)\] showed the statistical extremely significant difference in comparison between different genotypes. A similar result was obtained in FBG level of male patients (p=0.0296). In female patients, only DBP showed slightly significant change (p=0.0610) with respect to different genotypes. After one year treatment of mono drug therapy (BBs/diuretics/CCBs), only fasting blood glucose levels of patients treated with diuretics showed statistical slightly significant difference in both the genders (p=0.022: male and p=0.029:female patients) when compared between different genotypes. Parallel results were obtained in case of combination drug therapy (BBs with diuretic) showed moderate significant in fasting blood glucose levels. Other parameters failed to show any statistical significant difference.

The data (Table **[6](#t6){ref-type="table"}**) represented the genotype distribution with respect to drug therapy in male and female of EHNOD patients. Baseline of SBP, DBP and FBG of both male and female genotypes were found non-significant when compared between different genotypes (GG/TG/TT). After one year treated with different drugs, no significant changes were observed in any of drug treatment of male patients between different genotypes in SBP, DBP and FBG levels. In case of female patients, a slight significant difference (p=0.0413) was found in FBG level with diuretic therapy only.

The genotype wise average fall in SBP in EH patients with different drug therapies is given in Fig. **[2](#f2){ref-type="fig"}**. The best results were obtained in the combination of BB with CCB in TT genotype followed by CCB mono therapy. In other genotypes, diuretic with CCB and BB with diuretic were also effective. BB mono therapy was least effective in all genotypes. Almost same trend was followed for average fall in DBP (Fig. **[2](#f2){ref-type="fig"}**). Here also BB+CCB were most effective combination followed by CCB mono therapy. In both blood pressures (SBP and DBP), the combination drug therapies were most effective than mono drug therapies. Overall, all drug therapies were effective in controlling blood pressure. Fig. **[3](#f3){ref-type="fig"}** represents the average difference in the FBG level in EH patients after treatment with different antihypertensive drugs. A positive value represent the fall in FBG while negative value represents hike in FBG level. Most hike in FBG level was observed with diuretic treatment in TT genotype followed by TG genotype and further GG genotypes. A combination of diuretic with BB also elevates the FBG level in TG genotype followed by TT genotype whereas GG genotype showed protective effect with fall in FBG level. Other drug therapies were safe and no rise in FBG was observed.

Similarly, in EHNOD patients, most falls in SBP (Fig. **[2](#f2){ref-type="fig"}**) was observed in CCB mono therapy followed by diuretic alone and in combination with BB in TT genotype. All other drug therapies were equally effective in all genotypes. While fall in DBP (Fig. **[2](#f2){ref-type="fig"}**) was best achieved in combination of diuretic with CCB in GG genotype followed by diuretic + BB combination and CCB monotherapy in TT genotype. All other combinations were equally effective in all genotypes. Fig. (**[4](#f4){ref-type="fig"}**) represents the average fall in FBG level in different genotypes after different antihypertensive drug treatment. Effective fall in FBG level was achieved with all drug therapies except diuretic in which FBG level was observed to rise in TT genotype.

4. DISCUSSION {#sec4}
=============

In the present study, we evaluated the possible association of different polymorphic alleles of ADD1 gene with antihypertensive therapy (especially diuretics as mono therapy or as combination therapy) and new onset of diabetes in EH patients in rural population of Haryana. The prevalence of essential hypertension in this population was found around 40% as reported in previous studies \[[@r27], [@r28]\], therefore, it was suitable to conduct the study on the given population to find the correlation of antihypertensive therapy and new onset of diabetes in EH patients using pharmacogenomics tool. Our results indicated variant T allele (either TG heterozygous or TT homozygous) of ADD1 gene as the independent risk factor for new onset of diabetes under the influence of diuretic therapy. The study population was grouped as normotensives, EH and EHNOD groups.

The base line parameters (clinical and anthropometric) of these groups were compared with overall population, male and female population respectively (Table **[1](#t1){ref-type="table"}**). Data showed a higher statistical significance difference (*p\<0.0001*) at p value for different anthropometric parameters (Weight, BMI, WC, HC, W/H ratio) in all populations. The average duration of hypertension in EH and EHNOD groups were statistically non-significant. All clinical parameters (SBP, DBP and FBG level) were highly significant for EH and EHNOD groups when compared with normotensives. So, the study of baseline parameters suggested that different anthropometric parameters were indicative of risk factors for EH in both EH and EHNOD groups when compared with normal population. However, age and height were not significant for all comparisons and could not be taken as the indicator of risk factor for EH.

The comparison of the genotypic and allelic frequency distribution (G allele and T allele) among EH and normotensive group (Table **[2](#t2){ref-type="table"}**) showed a higher percentage of GG genotype as compared to TG and TT genotypes and hence higher G allele frequency than T allele in EH but it was non-significant when compared with that of normotensive group. While the genotypic and allelic frequency distribution among EHNOD and normotensive group (Table **[2](#t2){ref-type="table"}**) showed a significant difference (p=0.0008) in T allele frequency of EHNOD group when compared with normotensives. Therefore, the data showed a positive association between EHNOD and TT genotypic polymorphism which may indicate that T allele as the probable risk factor for new onset of diabetes in hypertensive population.

The genotype wise comparison of all anthropometric and clinical parameters in overall EH population (Table **[3](#t3){ref-type="table"}**) revealed that few of the anthropometric parameters were non-significant like weight, BMI, WC, HC and W/H ratio. However, clinical parameters and anthropometric parameters of essential hypertensive were showing extremely statistical significant. In male population (Table **[3](#t3){ref-type="table"}**), the statistical data suggested that p value were highly significant for age, SBP, DBP, FBG levels and duration of hypertension which signified the clear difference in wild type and variant type allele in terms of clinical parameters. But other anthropometric parameters such as weight, body mass index, WC, HC and W/H ratio were found to be statistical non-significant at p value. In female population (Table **[3](#t3){ref-type="table"}**), it showed statistical significant difference in DBP, FBG levels, WC and duration of hypertension. All other anthropometric parameters were non-significant.

Similarly, the genotype wise comparison of different anthropometric parameters in overall population of EHNOD (Table **[4](#t4){ref-type="table"}**) revealed significant difference in age, weight and height. While in male patients (Table **[4](#t4){ref-type="table"}**), it showed significant difference only in BMI and in female patients, it showed statistically significant difference only in age. All other parameters showed non-significant results.

Therefore, the above results revealed that there was a slight difference in wild type and variant type genotypes of ADD1 gene with respect to different clinical and anthropometric parameters. Although this difference was minor and from the data, it was not observed properly but it suggested that variant T allele as the risk factor for metabolic disease *via* salt sensitivity. However, contradictory results were given by Ranade *et al.,* 2000 \[[@r29]\] and Ramu *et al.,* 2010 on Indian population \[[@r16]\].

The effect of first line antihypertensive drug therapy on different genotypes of male and female population of hypertensive patients (as mono therapy or as combination therapy) was evaluated by comparing the genotype wise clinical parameters (SBP, DBP and FBG) at baseline and after one year of drug therapy with different drugs such as BB, diuretics, and CCB (Table **[5](#t5){ref-type="table"}**). One year period for observation of patient's clinical parameters was followed to assess the long term effect of different antihypertensive drug therapies on these clinical parameters with respect to genotype of patients. Among mono drug therapy of BB, no significant difference was observed in SBP, DBP and FBG level in between GG, TG and TT genotype both in males and females. Monotherapy of CCB showed somewhat protective effect on blood glucose level with better management of hypertension. But after one year of diuretic treatment patients, FBG level was significantly different among different genotypes in both males (p=0.0227) as well as females (p=0.0292) of EH group. TG and TT genotypes showed elevated blood glucose level as compared to GG genotype in both male and female EH patients. The combination therapy of diuretic with BB also elevated the blood glucose level in T allele carrying male (p=0.0023) and female patients (p=0.0079). However, combination of diuretic with CCB and other drug combinations were safe and effectively controlled the blood pressure.

In EHNOD patients, the antihypertensive drug therapy effectively controlled the blood pressure in all genotypes. No significant difference was observed in FBG level of male population after one year treatment but a female patients showed a slight significant difference (p=0.0413) with diuretic therapy (Table **[6](#t6){ref-type="table"}**). In both monotherapy (diuretics) and in combination therapy (diuretic with BB) of male and female patients, it showed fluctuations (given as standard deviations) in FBG levels as it was very high and the results were non-significant despite anti diabetic treatment in variant T allele (GT and TT genotypes) as compared to G allele. However, no such type of fluctuation in FBG level was observed with other mono drug therapy or combination drug therapies and these were found quite effective.

Therefore, from data (Fig. **[2](#f2){ref-type="fig"}**), we can suggest that all antihypertensive drug therapies either as monotherapy or in combination effectively controlled both the blood pressures (SBP and DBP) in EH patients and EHNOD patients. However, diuretic either as mono drug therapy or in combination with BB in both EH and EHNOD patients were reported to elevate FBG level in T allele (either as TG or TT genotype or both) of ADD1 gene. In EHNOD patients, diuretic mono therapy was associated with elevated FBG level in TT genotype but the combination of diuretic with BB was safe in this group.

From our findings, we may suggest that those patients who were treated with chronic diuretic therapy whether it was monotherapy or in combination therapy, the FBG levels may chance to elevate due to disturbance in glucose homeostasis. The probable mechanism may lie behind the fact that variant T allele of ADD1 was suggested to be associated with the enhanced renal Na^+^ re-absorption through Na^+^-K^+^ ATPase pump \[[@r30], [@r31]\] which in turn eliminate more K^+^ ions to balance the ionic potential across the renal membrane \[[@r16], [@r17]\]. But a higher K^+^ elimination is associated with low insulin secretion and insulin insensitivity and hence leads to glycaemic dysregulation \[[@r31], [@r32]\] as described in Fig. (**[4](#f4){ref-type="fig"}**).

Therefore, in our results, we can easily show the evidence that, those individuals who are having T allele may prone to high risk of essential hypertension as well as the new onset of diabetes mellitus after chronic diuretic therapy in essential hypertensive patients.

CONCLUSION
==========

Our study suggested that variant T allele of the ADD1 gene may be considered as the risk factor for the development of new onset of diabetes in EH patients of Haryanvi population.
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![Representative image of agarose gel electrophoresis of showing the Gly460Trp polymorphism of ADD1 gene. Panel A represents the G allele specific primer amplification (F614G) and Panel B, T allele specific (F614T). Lane L represents the 100 bp DNA ladder. Appearance of band in both panel shows TG genotype (lane 3, 5, 6) while lane 1, 2, 7 represents GG genotype and lane 4 represents TT genotype.](CHR-15-123_F1){#f1}

![(**A**) Average fall in systolic blood pressure in EH patients among different genotypes with different antihypertensive therapies. (**B**) Average fall in diastolic blood pressure in EH patients among different genotypes with different antihypertensive therapies after one year. (**C**) Average fall in systolic blood pressure in EHNOD patients among different genotypes with different antihypertensive therapies. (**D**) Average fall in diastolic blood pressure in EHNOD patients among different genotypes with different antihypertensive therapies after one year.](CHR-15-123_F2){#f2}

![Average change in fasting blood glucose level in EH patients among different genotypes after different antihypertensive therapies treatment after one year.](CHR-15-123_F3){#f3}

![Average change in fasting blood glucose level in EHNOD patients among different genotypes after different antihypertensive therapies treatment after one year.](CHR-15-123_F4){#f4}

###### Base line parameters of total population and gender based specific.

                                       **Total population**   **Male**     **Female**                                                                                                 
  ------------------------------------ ---------------------- ------------ ------------ -------- ----------- ----------- ------------- -------- ----------- ------------ ------------ --------
  **Age (yrs)**                        51.8±11.9              53.4±10.8    54.9±9.2     0.005    52.2±11.7   54.7±13.5   53.9±9.1      0.0368   51.3±12.2   52.6±9.0     55.4±9.3     0.0001
  **SBP (mmHg)**                       123.3±4.9              152.5±10.2   155.4±8.1    0.0001   123.5±5.6   153.7±6.3   156.19±5.7    0.0001   123.1±4.0   151.9±11.8   155±9.1      0.0001
  **DBP (mmHg)**                       81.5±3.7               91.8±2.6     92.3±2.4     0.0001   81.3±4.1    91.2±2.15   92.5±2.2      0.0001   81.7±3.2    92.1±2.7     92.2±2.5     0.0001
  **FBG (mg/dl)**                      97.1±6.6               107.2±7.8    207.2±81.0   0.0001   96.8±6.0    106.7±7.1   186.25±65.2   0.0001   97.6±7.2    107.4±8.2    217.8±86.1   0.0001
  **Weight (kg)**                      63.4±8.8               71.9±7.5     75.9±8.6     0.0001   67.8±8.5    74.8±8.34   82.2±6.9      0.0001   58.1±5.7    70.4±6.59    72.7±7.6     0.0001
  **Height (cm)**                      158.5±9.3              156.8±8.7    158.0±8.3    0.088    164.6±7.0   165.0±6.9   166.84.2      0.0002   150.8±5.2   152.4±6.0    153.6±6.1    0.0005
  **BMI (kg/m^2^)**                    25.1±1.8               28.5±2.3     30.3±1.7     0.0001   24.9±1.7    27.3±1.6    29.5±1.5      0.0001   25.5±1.9    29.2±2.3     30.7±1.7     0.0001
  **WC (cm)**                          76.3±7.5               94.1±7.0     103.1±11.3   0.0001   77.3±6.8    88.6±6.7    110.5±12.5    0.0001   75.1±8.1    97.0±5.3     99.4±8.6     0.0001
  **HC (cm)**                          90.5±7.1               105.5±10.2   104.9±12.6   0.0001   87.3±6.64   94.2±4.96   114.2±12.7    0.0001   94.5±5.5    111.7±6.2    100.2±9.7    0.0001
  **W/H Ratio**                        0.85±0.0               0.90±0.0     0.99±0.0     0.0001   0.89±0.0    0.94±0.0    0.97±0.0      0.0001   0.79±0.0    0.87±0.0     0.99±0.0     0.0001
  **Duration of hypertension (yrs)**   \-                     4.70±4.1     7.91±4.5     \-       \-          5.89±5.2    7±4.3         \-       \-          4.06±3.1     8.36±4.57    \-
  **Duration of diabetes (yrs)**                              \-           5.72±4.3     \-                   \-                        \-       \-                       5.97±4.5     \-

###### Distribution of ADD-1 genotypes and alleles in cases and normal population.

  ----------------------------------------------------------------------
  **Genotypes**   **Groups**    **Groups**                  
  --------------- ------------- ------------- ------------- ------------
  **Gly/Gly**     190 (70.4%)   182 (67.4%)   190 (70.4%)   165 (68.8)

  **Gly/Trp**     70 (25.9%)    75 (27.8%)    70 (25.9%)    60 (25%)

  **Trp/Trp**     10 (3.7%)     13 (4.8%)     10 (3.7%)     15 (6.3%)

  **P value**\    0.692\        0.813         0.412\        0.813
  **Gly**         0.833                       0.833         

  **Try**\        0.167\        0.187         0.167\        0.707
  **P value**     0.383                       0.380         
  ----------------------------------------------------------------------

###### Distribution of genotypes with respect to various parameters in gender based and total population of essential hypertension patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           **Total population**   **Male**     **Female**                                                                                                  
  ------------------------ ---------------------- ------------ ------------ ------- ----------- ----------- ----------- -------- ------------- ------------- ------------- --------
  **Age (yrs)**            52.5±9.7               55.8±12.5    51.6±14.0    0.005   51.6±11.3   60.6±15.5   47.5±3.5    0.0055   52.91±8.9     51.95±7.4     54.09±13.1    0.733

  **SBP (mmHg)**           152.4±10.7             153.0±8.7    151.6±11.6   0.008   152.3±6.7   156.3±4.5   150±5.6     0.0087   152.44±12.2   150.39±10.3   152.64±12.5   0.621

  **DBP (mmHg)**           91.8±2.8               91.8±1.9     91.5±2.9     0.000   90.4±2.1    92.5±1.4    90±2.8      0.0001   92.41±2.9     91.22±2.1     92.09±2.8     0.061

  **FBG (mg/dl)**          107.3±7.4              107.0±8.4    105.5±10.3   0.029   105.4±5.5   109.2±8.9   101.5±3.5   0.0296   108.26±8.0    105.24±7.5    107±10.6      0.121

  **Weight (kg)**          71.7±7.5               72.4±6.7     71.4±11.4    0.158   75±8.4      73.9±8.0    85.5±4.9    0.1584   70.31±6.7     71.24±5.2     68.27±9.2     0.401

  **Height (cm)**          156.2±8.8              158.0±7.5    159±11.5     0.009   165.1±7.3   163.9±5.2   179±1.4     0.0095   152±6         153.22±5.4    155.64±7.1    0.107

  **BMI (kg/m^2^)**        28.6±2.1               28.5±2.5     28.1±2.7     0.841   27.3±1.     27.4±2.0    26.68±1.1   0.8412   29.23±2.1     29.47±2.6     28.3±2.9      0.341

  **WC (cm)**              94.9±6.6               92.2±7.9     93.2±4.8     0.276   88.7±6.5    88.1±7.0    96±5.6      0.2763   97.91±4.2     95.59±7.1     93.73±5.0     0.004

  **HC (cm)**              106.4±10.3             103.0±10.0   108.5±6.9    0.420   93.9±4.8    94.4±5.2    98.5±0.7    0.4207   112.41±5.9    110.12±7.1    110.18±5.9    0.0896

  **W/H Ratio**            0.9±0.0                0.9±0.0      0.86±0.0     0.249   0.95±0.0    0.93±0.0    0.98±0.0    0.2493   0.87±0.0      0.87±0.0      0.85±0.05     0.3327

  **Duration of**\         4.12±3.3               5.9±5.1      5.4±5.1      0.005   4.6±3.9     8.15±6.5    3±2.8       0.0057   3.81±3.0      4.2±2.7       6.55±5.0      0.0208
  **hypertension (yrs)**                                                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Distribution of genotypes with respect to various parameters in gender based and total population of essential hypertension with new onset of diabetes.

                                       **Total population**   **Male**     **Female**                                                                                                    
  ------------------------------------ ---------------------- ------------ ------------- -------- ------------ ------------ ------------ -------- ------------ ------------ ------------ --------
  **Age (yrs)**                        55.8±8.9               52.0±9.8     56.4±8.8      0.0229   54.1±9.1     50.7±6.7     60.2±11.8    0.1401   56.8±8.7     52.4±10.5    54.5±6.9     0.0263
  **SBP (mmHg)**                       155.2±7.1              155.4±10.0   156.8±10.9    0.7776   156.1±5.7    154.3±5.3    160.8±4.7    0.1024   154.6±7.8    155.7±10.9   154.8±12.7   0.8048
  **DBP (mmHg)**                       92.2±2.3               92.1±2.7     93.33±3.0     0.2338   92.5±2.2     92.1±2.5     92.4±1.82    0.8253   92.1±2.3     92.1±2.7     93.8±3.55    0.1330
  **FBG (mg/dl)**                      207.4±79.7             213.7±87.4   179.93±65.6   0.3523   187.2±64.0   197.3±68.7   144.8±68.4   0.3038   219.5±85.8   218.3±92.1   197.5±59.8   0.7433
  **Weight (kg)**                      76.8±8.5               73.3±8.3     76.27±9.35    0.0261   82.3±6.4     80.9±9.8     84.6±5.9     0.5991   73.5±7.9     71.2±6.6     72.1±7.9     0.2254
  **Height (cm)**                      158.7±8.3              156.2±8.3    157.13±7.8    0.1206   166.6±3.5    167.8±7.1    166.4±2.1    0.6271   154.0±6.6    153±5.1      152.5±4.6    0.5502
  **BMI (kg/m^2^)**                    30.4±1.7               30.0±1.8     30.78±1.6     0.1717   29.6±1.5     28.6±1.1     30.54±1.7    0.0333   30.9±1.6     30.3±1.7     30.9±1.5     0.1966
  **WC (cm)**                          104.0±11.4             101.5±10.9   99.2±10.7     0.1342   110.2±11.9   115.6±12.2   101±16.0     0.0769   100.3±9.4    97.6±6.5     98.3±7.8     0.2075
  **HC (cm)**                          105.9±13.2             103.2±10.9   100.53±11.1   0.1444   114.6±12.7   116.1±10.5   105±16.1     0.2289   100.7±10.6   99.6±8.0     98.3±7.8     0.6794
  **W/H Ratio**                        0.99±0.05              0.99±0.05    0.99±0.05     0.9999   0.96±0.04    0.99±0.05    0.96±0.0     0.0708   1±0.06       0.98±0.0     1±0.0        0.1302
  **Duration of hypertension (yrs)**   7.8±4.5                8.2±4.51     7.0±4.0       0.6619   7.1±4.2      6.54±4.9     6.8±4.7      0.9075   8.32±4.75    8.6±4.3      7.2±3.9      0.6415

###### Distribution of genotypes with respect to various parameters in male and female of essential hypertensive patients before and after drug treatment.

  **Drug Treatment**             **Genotypes**                                                                                       
  ------------------------------ --------------- -------------- ------------ ---------- -------------- -------------- -------------- --------
  **Base line readings**                                                                                                             
  Number                         59              34             2                       123            41             11             
  SBP                            152.37±6.75     156.32±4.56    150±5.66     0.0087     152.44±12.26   150.39±10.36   152.64±12.56   0.6210
  DBP                            90.46±2.11      92.59±1.44     90±2.83      \<0.0001   92.41±2.95     91.22±2.1      92.09±2.81     0.0610
  FBP                            105.49±5.59     109.21±8.93    101.5±3.54   0.0296     108.26±8.09    105.24±7.58    107±10.64      0.1216
  **Readings after one year**                                                                                                        
  **Mono drug therapy**                                                                                                              
  **BB**                         6               4              1                       17             2              2              
  SBP                            133.33±5.68     135.25±3.95    132          0.5758     131±7.38       131.5±10.61    134.5±4.95     0.8238
  DBP                            86.17±2.93      87.75±3.86     86           0.4807     89.29±5.63     88.5±7.78      90.5±2.12      0.0935
  FBP                            106.33±5.57     110.75±7.46    110          0.3120     109.41±10.1    111.5±9.19     113.5±9.19     0.8413
  **Diuretic**                   7               3              1                       15             4              2              
  SBP                            129.86±6.36     125.33±5.86    121          0.3233     128.27±6.69    127.5±9.75     125.5±4.95     0.8628
  DBP                            85.71±5.22      85.33±4.16     82           0.9146     87.13±6.52     88.25±6.24     88.5±6.36      0.9431
  FBP                            109.29±9.6      128.33±10.41   141          0.0227     110.07±11.15   117.75±12.5    135.5±17.68    0.0292
  **CCB**                        9               6                                      24             5              1              
  SBP                            127.33±6.12     131.17±6.37    \-           0.2623     132.75±6.22    128.6±9.26     134            0.2223
  DBP                            87.11±4.81      86.17±4.45     \-           0.7090     89.46±6.37     87.4±5.77      88             0.5106
  FBP                            103.44±5.59     101.83±6.79    \-           0.9945     106.83±8.08    105.8±7.82     104            0.7964
  **Combination drug therapy**                                                                                                       
  **Diuretic + BB**              14              10                                     27             15             2              
  SBP                            121.79±4.39     124.7±5.06     \-           0.1470     123.74±4.93    124.47±7.76    126.5±7.78     0.7973
  DBP                            82.43±3.52      84.1±3.7       \-           0.2739     81.93±2.70     82.33±4.29     82.5±3.54      0.9193
  FBP                            105.29±5.88     115.5±8.7      \-           0.0023     106.48±10.6    117.53±14.86   126.5±16.26    0.0079
  **BB + CCB**                   9               5                                      22             10             2              
  SBP                            123.67±4.42     121.6±5.5      \-           0.4550     124.82±6.46    121.8±4.89     125±5.66       0.4178
  DBP                            83.22±4.24      83.2±4.32      \-           0.9934     83.68±3.93     82.6±3.53      83.5±4.95      0.7643
  FBP                            99.67±6.32      101.6±6.43     \-           0.5962     103.59±10.26   106.6±8.11     102.5±9.19     0.6896
  **Diuretic + CCB**             14              6                                      18             5              2              
  SBP                            119.86±5.19     121.67±4.03    \-           0.4584     120.83±4.67    120.6±7.83     126.5±7.78     0.3903
  DBP                            80.43±3.23      82.17±3.43     \-           0.2923     81.17±2.53     83.4±5.18      83.5±6.36      0.3496
  FBP                            100.86±4.93     98.17±4.02     \-           0.2556     100.89±10.44   99.8±9.65      100.5±6.36     0.9775

###### Distribution of genotypes with respect to various parameters in male and female of essential hypertensive new onset of diabetes patients before and after drug treatment.

  **Drug Treatment**             **Genotypes**                                                                                      
  ------------------------------ --------------- -------------- ------------- -------- -------------- -------------- -------------- --------
  **Base line readings**                                                                                                            
  Number                         62              13             5                      103            47             10             
  SBP                            156.19±5.74     154.38±5.33    160.8±4.76    0.1024   154.68±7.81    155.74±10.99   154.8±12.77    0.8048
  DBP                            92.58±2.28      92.15±2.54     92.4±1.82     0.8253   92.12±2.32     92.11±2.79     93.8±3.55      0.1330
  FBP                            187.27±64.09    197.31±68.71   144.8±68.43   0.3038   219.55±85.89   218.32±92.12   197.5±59.89    0.7433
  **Readings after one year**                                                                                                       
  **Mono drug therapy**                                                                                                             
  **BB**                         6               2              \-                     8              3              \-             
  SBP                            134.33±4.41     131.5±9.19     \-            0.5520   131.25±4.98    133.33±5.77    \-             0.5667
  DBP                            84.83±3.49      82.5±3.54      \-            0.4458   83.75±3.49     83.67±2.08     \-             0.9716
  FBP                            100.83±26.55    101.5±37.48    \-            0.9781   116.38±51.3    110.67±28.22   \-             0.8620
  **Diuretic**                   5               2              2                      10             4              3              
  SBP                            132.2±8.23      129.5±7.78     131.5±9.19    0.9284   129.5±8.4      127.75±6.65    132.67±6.66    0.7151
  DBP                            85.8±4.27       86.5±4.95      86±7.07       0.9859   86.5±4.86      83.25±3.40     85.33±4.16     0.4891
  FBP                            110.2±24.94     127.5±74.25    166.5±77.07   0.4299   117.5±40.52    142.5±43.27    193.33±38.19   0.0413
  **CCB**                        9               2              1                      17             4                             
  SBP                            130.78±6.36     128.5±6.36     131           0.6574   128.65±6.58    132.25±7.14    \-             0.3437
  DBP                            83.67±3.12      84.5±3.54      85            0.7453   84.94±4.35     83.75±2.5      \-             0.6087
  FBP                            104.33±16.43    103.5±17.68    105           0.9503   106.06±25.62   103.25±20.55   \-             0.8412
  **Combination drug therapy**                                                                                                      
  **Diuretic + BB**              12              2                                     16             6              2              
  SBP                            128.25±7.2      132±5.66       \-            0.5015   132.19±7.54    128.83±7.05    129.5±9.19     0.6211
  DBP                            85.33±4.83      85±4.24        \-            0.9295   87.25±4.3      85.17±3.31     84.5±4.95      0.4570
  FBP                            115.58±36.48    137.5±36.06    \-            0.4463   122.63±49.19   149.5±50.48    190.5±68.59    0.1537
  **BB + CCB**                   20              2              1                      31             16             2              
  SBP                            126.15±5.47     125±7.07       130           0.7832   125.71±5.09    128.69±5.41    126.5±6.36     0.1909
  DBP                            84.3±4.11       82±2.83        85            0.4534   83.87±3.88     84.63±3.18     83.5±3.54      0.7753
  FBP                            106.4±18.88     108.5±17.68    170           0.8819   108.03±26.3    109.38±38.72   102.5±38.89    0.9558
  **Diuretic + CCB**             10              3              1                      21             14             3              
  SBP                            128.7±6.95      123.67±4.04    128           0.2659   127.33±4.76    130.43±7.27    128.67±7.23    0.3329
  DBP                            83.5±3.81       81.67±2.08     84            0.4512   81.86±3.14     84.43±3.90     83.67±3.79     0.1091
  FBP                            102.6±14.05     108.33±19.73   108           0.5794   103.1±16.34    107.43±49.31   110.33±39.63   0.9004
